Literature DB >> 21099211

Ox brain versus rabbit brain thromboplastin assays are the best tool for a preliminary diagnosis of the Arg304Gln factor VII defect (FVII Padua).

A Girolami1, G Berti de Marinis, E Bonamigo, R Sartori, S Vettore.   

Abstract

Factor VII (FVII) deficiency, the most frequent defect among the rare bleeding disorders, is commonly divided into type I and type II. In the former, there is a concomitant decrease in FVII activity and antigen. In the latter, there is a clear discrepancy between activity which is low and antigen which is normal or nearly normal. FVII Padua (Arg304Gln) is characterized by different reactivity towards different tissue thromboplastins. FVII levels were assayed by the use of different tissue thromboplastins, namely rabbit brain, human placenta, human recombinant and ox brain thromboplastin, in 6 homozygous patients. Cases reported in the literature were also evaluated. Ox brain thromboplastins yielded normal values, whereas human tissue or recombinant human thromboplastins yielded only slightly higher levels of activity than those obtained with rabbit brain reagents. The ox brain versus rabbit brain ratio was about 22, whereas the ratio for human placenta or human recombinant versus rabbit brain thromboplastin was only about 5. The FVII antigen versus rabbit brain, human tissue and ox brain activity ratios were 24.8, 4.3 and 1.1, respectively. These results indicate that the ox brain versus the rabbit brain thromboplastin ratio supplies a wider difference than the one between human tissue and rabbit brain. The antigen/ox brain activity ratio of 1.1 fully confirms this assertion.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099211     DOI: 10.1159/000321534

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

1.  Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.

Authors:  Alessio Branchini; Lara Rizzotto; Guglielmo Mariani; Mariasanta Napolitano; Mario Lapecorella; Muriel Giansily-Blaizot; Rosella Mari; Alessandro Canella; Mirko Pinotti; Francesco Bernardi
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Conformational Changes of Congenital FVII Variants with Defective Binding to Tissue Factor ARG304GLN (FVII Padua), ARG 304TRP (FVII Nagoya) and ARG79GLN (FVII Shinjo or Tondabayashi).

Authors:  Andrea Cristiani; Silvia Vettore; Luisa Sambado; Alessandro Bulfone; Stefano Moro; Antonio Girolami
Journal:  Int J Biomed Sci       Date:  2013-12

3.  Compound Heterozygous Factor VII Deficiency c.1025G>A p.(Arg342Gln) With Novel Missense Variant c.194C>G p.(Ala65Gly).

Authors:  Christian Aledia Gallardo; Lester Jun Long Wong; Christina Lai Lin Sum; Liuh Ling Goh; Kiat Hoe Ong
Journal:  J Hematol       Date:  2022-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.